sr141716 has been researched along with Absence Status in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pitkänen, A | 1 |
| Dudek, FE; Pouliot, WA; Rossi, CA; Staley, KJ | 1 |
1 review(s) available for sr141716 and Absence Status
| Article | Year |
|---|---|
Therapeutic approaches to epileptogenesis--hope on the horizon.
Topics: Animals; Anticonvulsants; Epilepsy; Epilepsy, Post-Traumatic; Humans; Imidazoles; Immunosuppressive Agents; Piperidines; Pyrazoles; Rats; Rimonabant; Sirolimus; Status Epilepticus; Terminology as Topic | 2010 |
1 other study(ies) available for sr141716 and Absence Status
| Article | Year |
|---|---|
The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat.
Topics: Age Factors; Animals; Brain; Cannabinoid Receptor Antagonists; Convulsants; Disease Models, Animal; Electroencephalography; Epilepsy; Kainic Acid; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Recurrence; Rimonabant; Status Epilepticus | 2010 |